STP938 for high-risk essential thrombocythemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with essential thrombocythemia by standard guidelines
- Considered high-risk for complications like blood clots or bleeding
- Platelet count above 600 x 10⁹/L and need treatment to reduce it
- Could not tolerate or did not respond well to hydroxycarbamide therapy
- Not currently on other ET treatments (you may need a washout period)
- Generally healthy, with normal liver function, blood clotting, and ability to care for yourself
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
This trial tests a new injectable medicine (Peginterferon α-2b) for people with essential thrombocythemia (ET) whose disease is not controlled by hydroxyurea (HU) or who cannot tolerate HU. It aims to help lower high platelet counts and reduce the risk of clots or bleeding.
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
This study tests how well a blood-thinning medication called clopidogrel works in patients with essential thrombocythemia (a condition where your body makes too many platelets). Researchers want to understand why some patients respond better to this medication than others, which could help doctors choose the best treatment for you.
This Phase 1/2 study tests dencatistat (STP938) to treat adults whose B-cell or T-cell lymphoma has come back or not responded to treatment. It looks at safety, the best dose, and whether it can shrink tumors or improve disease control when standard options have not helped.
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
Hear when a new Essential Thrombocythaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.